Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Iptacopan in complement inhibitor-naive adults with atypical hemolytic uremic syndrome
2020-005186-13Phase 3Active
- Sponsor
- Novartis
- Start
- May 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of Iptacopan in atypical hemolytic uremic syndrome (aHUS), sponsored by Novartis. Primary endpoints: Complete thrombotic microangiopathy response during 26 weeks and Complete TMA response without PE/PI and anti-C5 antibody. Started May 2021; status: active.
02
Drugs
Iptacopan
03
Conditions
atypical hemolytic uremic syndrome (aHUS)
Beyond the preview
Go deeper on 2020-005186-13.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-005186-13.